海外の治験の状況「1」での検索結果
2039件の検索結果
- 進捗状況
- 試験名
- 対象疾患名
- 地域
- 登録日
Authorised
- A Clinical Trial to Compare the effectiveness and safety of Gan & Lee Pharmaceuticals Insulin Glargine Injection to Lantus® (Insulin Glargine Injection) in Adults with Type 1 Diabetes Mellitus
- Type 1 diabetes mellitus br>MedDRA version: 20.0 Level: PT Classification code 10067584 Term: Type 1 diabetes mellitus System Organ Class: 10027433 - Metabolism and nutrition disorders ;Therapeutic area: Diseases [C] - Nutritional and Metabolic Diseases [C18]
- Czech Republic, Germany, Hungary, Poland, Russian Federation, Spain, Ukraine, United States
- 2017-11-23
Authorised
- Phase 2/3 study of rogaratinib (pan FGFR inhibitor) vs chemotherapy in patients with locally advanced or metastatic urothelial carcinoma with a high amount of specific cell growth factor receptors 1 and 3 (FGFR1 and 3) in the tumor cells
- mRNA FGF receptor 1 and 3 positive locally advanced or metastatic urothelial carcinoma progressed after prior platinum-containing chemotherapy MedDRA version: 20.0 Level: LLT Classification code 10064467 Term: Urothelial carcinoma System Organ Class: 100000004864 ;Therapeutic area: Diseases [C] - Cancer [C04]
- Australia, Austria, Belgium, Brazil, Canada, China, Czech Republic, Denmark, Finland, France, Germany, Hong Kong, Hungary, Ireland, Israel, Italy, Japan, Korea, Democratic People's Republic of, Netherlands, Poland, Portugal, Russian Federation, Singapore, Slovakia, Spain, Sweden, Switzerland, Taiwan, United Kingdom, United States
- 2018-01-18
Authorised
- Is treatment with octreotide effective in patients with head-and-neck paraganglioma? - octreotide in head and neck paraganglioma
- Patients with head-and-neck paraganglioma
- Netherlands
- 2006-05-12
Authorised
- A Randomized, Double-Blind, Placebo-controlled, Single-center Phase 1 Pilot Study to Explore the Safety and Pharmacokinetics of a Single-Dose of DAPAglifozin as Add-on to Intravenous Insulin-Infusion in Adolescent and Adult Subjects with Type 1 Diabetes mellitus
- Type 1 Diabetes mellitus;Therapeutic area: Diseases [C] - Hormonal diseases [C19]
- Germany
- 2014-11-03
Authorised
- An open, 3-cohort, phase II trial testing oral administration of lucitanib in patients with FGFR1-amplified or non-amplified estrogen receptor positive metastatic breast cancer.
- FGFR1-amplified or non-amplified estrogen receptor positive metastatic breast cancer MedDRA version: 18.1 Level: PT Classification code 10055113 Term: Breast cancer metastatic System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) MedDRA version: 18.1 Level: LLT Classification code 10070575 Term: Estrogen receptor positive breast cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) ;Therapeutic area: Diseases [C] - Cancer [C04]
- Australia, Belgium, Canada, France, Germany, Hungary, Italy, Spain, United Kingdom
- 2013-06-12
Authorised
- In vivo induction of heme oxygenase-1 (HO-1) in the metabolic syndrome (MetS). Influence of heme arginate (Normosang) infusion on heme oxygenase-1 activity, endothelial dysfunction, insulin resistance and adipose tissue inflammation related to the metabolic syndrome - In vivo induction of HO in MetS.
- Subjects suffer from the metabolic syndrome. Effects of study medication on insulin resistance and vascular function will be studied respectively. MedDRA version: 12.1 Level: LLT Classification code 10022489 Term: Insulin resistance MedDRA version: 12.1 Level: LLT Classification code 10052066 Term: Metabolic syndrome MedDRA version: 12.1 Level: LLT Classification code 10048554 Term: Endothelial dysfunction
- Netherlands
- 2010-06-24
Authorised
- Phase III study to compare two different chemotherapy treatments to determine whether the first line with the three drugs + bevacizumab followed by a second line with the same regimen may provide better results than treatment with two drugs + bevacizumab is the first and the second treatment line
- METASTATIC COLORECTAL CANCER;Therapeutic area: Diseases [C] - Cancer [C04]
- Italy
- 2014-11-11
Authorised
- Phase I study of TARCEVA (Erlotinib Hydrochloride, OSI-774) as a single agent in children with refractory and relapsed malignant brain tumours and in combination with irradiation in newly diagnosed brain stem glioma. - Tarceva in paediatric brain tumours
- Refractory and relapsed malignant brain tumours and newly diagnosed brain stem glioma.
- Italy, United Kingdom
- 2005-06-21
Authorised
- A randomised open-label study comparing the safety and efficacy of ritonavir boosted lopinavir and 2-3N(t)RTI backbone versus ritonavir boosted lopinavir and raltegravir in participants virologically failing first-line NNRTI/2N(t)RTI therapy: the SECOND-LINE study. - SECOND-LINE
- Chronic HIV infection MedDRA version: 12.0 Level: LLT Classification code 10008919 Term: Chronic HIV infection
- France, Germany, Ireland, United Kingdom
- 2010-02-15
Authorised
- Gene Therapy for Leukocyte Adhesion Deficiency-I (LAD-I): A Phase I Clinical Trial to Evaluate the Safety and Efficacy of the Infusion of Autologous Hematopoietic Stem Cells Transduced with a Lentiviral Vector Encoding the ITGB2 Gene
- Leukocyte Adhesion Deficiency-I (LAD-I) MedDRA version: 20.0 Level: LLT Classification code 10018137 Term: Genetic anomalies of leukocytes System Organ Class: 100000004850 ;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]
- Spain
- 2018-08-02